We have shown that CD362+ UC-MSC therapy is compatible with antibiotic use during pneumonia, in some cases superior to antibiotic use, and can potentially enhance the overall well-being of the patient beyond what is seen with antibiotics alone. The gene discussed is SDC2; the disease is pneumonia.